MedPath

Fludarabine

Generic Name
Fludarabine
Brand Names
Fludara
Drug Type
Small Molecule
Chemical Formula
C10H12FN5O4
CAS Number
21679-14-1
Unique Ingredient Identifier
P2K93U8740
Background

Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication

For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions
B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 1
Terminated
Conditions
Neoplasms
Interventions
First Posted Date
2023-07-13
Last Posted Date
2024-11-13
Lead Sponsor
Adaptimmune
Target Recruit Count
5
Registration Number
NCT05943990
Locations
🇸🇪

GSK Investigational Site, Stockholm, Sweden

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Phase 1
Recruiting
Conditions
Ovarian Cancer
Adenocarcinoma
Pancreatic Cancer
Interventions
First Posted Date
2023-06-28
Last Posted Date
2024-12-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
51
Registration Number
NCT05922930
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

Phase 2
Recruiting
Conditions
Acute Myeloid Leukemia in Remission
Interventions
First Posted Date
2023-06-23
Last Posted Date
2023-11-15
Lead Sponsor
Nantes University Hospital
Target Recruit Count
302
Registration Number
NCT05917405
Locations
🇫🇷

CRLC Caen, Caen, France

🇫🇷

CHU Limoges, Limoges, France

🇫🇷

CHU Besançon, Besançon, France

and more 20 locations

CAR T-cell Therapy in Patients With Renal Dysfunction

Phase 2
Recruiting
Conditions
Non-hodgkin Lymphoma,B Cell
Acute Lymphoblastic Leukemia, Adult
Multiple Myeloma
Interventions
First Posted Date
2023-06-18
Last Posted Date
2024-12-16
Lead Sponsor
Northside Hospital, Inc.
Target Recruit Count
20
Registration Number
NCT05909059
Locations
🇺🇸

Caitlin Guzowski, Atlanta, Georgia, United States

Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency

Phase 2
Recruiting
Conditions
GATA2
Immunodeficiency
Interventions
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Drug: Post-Transplant Cyclophosphamide
Radiation: Total Body Irradiation
Procedure: Hematopoietic Cell Transplant
Drug: JSP191
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2023-06-18
Last Posted Date
2024-12-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
40
Registration Number
NCT05907746
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Delayed Tolerance Through Mixed Chimerism

Phase 1
Recruiting
Conditions
Kidney Failure
Kidney Transplant; Complications
Chimera
Interventions
Other: Bone Marrow Transplant
Procedure: Peripheral Blood Stem Cell Collection
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Siplizumab
First Posted Date
2023-06-12
Last Posted Date
2024-06-06
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
20
Registration Number
NCT05900401
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL

Phase 2
Recruiting
Conditions
Relapsed or Refractory Hodgkin Lymphoma
Peripheral T Cell Lymphoma
Interventions
First Posted Date
2023-06-01
Last Posted Date
2024-11-13
Lead Sponsor
Affimed GmbH
Target Recruit Count
154
Registration Number
NCT05883449
Locations
🇺🇸

UNC Immunotherapy Team, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

🇺🇸

O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States

🇺🇸

City of Hope National Medical Center, Duarte, California, United States

and more 12 locations

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2023-05-31
Last Posted Date
2024-04-12
Lead Sponsor
TCRCure Biopharma Ltd.
Target Recruit Count
18
Registration Number
NCT05881525
Locations
🇨🇳

TCRCure Biopharma Ltd., Chongqing, China

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Phase 2
Recruiting
Conditions
Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Transformed Chronic Lymphocytic Leukemia
Refractory Transformed Non-Hodgkin Lymphoma
Refractory Transformed B-cell Non-Hodgkin Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
Refractory Transformed
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: Leukapheresis
Biological: Lisocabtagene Maraleucel
Procedure: Lymph Node Biopsy
Procedure: Positron Emission Tomography
Drug: Zanubrutinib
First Posted Date
2023-05-24
Last Posted Date
2024-03-15
Lead Sponsor
Adam Kittai
Target Recruit Count
24
Registration Number
NCT05873712
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases

Phase 1
Recruiting
Conditions
Systemic Sclerosis
Systemic Lupus Erythematosus
Idiopathic Inflammatory Myopathy
Interventions
First Posted Date
2023-05-23
Last Posted Date
2024-12-19
Lead Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Target Recruit Count
129
Registration Number
NCT05869955
Locations
🇪🇸

Hospital Universitario Reina Sofia, Cordoba, Spain

🇺🇸

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 51 locations
© Copyright 2025. All Rights Reserved by MedPath